Pharmacodynamic modeling of the antihypertensive response to amlodipine
- PMID: 8375125
- DOI: 10.1038/clpt.1993.151
Pharmacodynamic modeling of the antihypertensive response to amlodipine
Abstract
The distinctive pharmacokinetic characteristics of amlodipine, particularly the long half-life, are presumed to translate directly to a prolonged duration of action, but the concentration-effect relationship for the antihypertensive response has not been clearly established. In this study of 12 patients with essential hypertension, treatment with 5 mg amlodipine once daily has been evaluated with use of an integrated pharmacokinetic-pharmacodynamic model to calculate individual patient responsiveness for the decrease in blood pressure per unit change in drug concentration. Amlodipine concentrations were well correlated with the placebo-corrected reductions in blood pressure in individual patients and responsiveness, for example, for erect systolic blood pressure was -3.1 +/- 0.9 mm Hg/ng/ml. By characterizing the concentration-effect relationships in individual patients, this study has confirmed that the plasma concentration-time profile is an appropriate index of the effect-time profile, as reflected by an antihypertensive response that is sustained throughout 24 hours with relatively little trough-to-peak variability.
Similar articles
-
Amlodipine; clinical relevance of a unique pharmacokinetic profile.J Cardiovasc Pharmacol. 1993;22 Suppl A:S6-8. J Cardiovasc Pharmacol. 1993. PMID: 7522286 Review.
-
An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension.Am J Cardiol. 1994 Jan 27;73(3):10A-17A. doi: 10.1016/0002-9149(94)90269-0. Am J Cardiol. 1994. PMID: 8310971
-
Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.Clin Ther. 2007 Sep;29(9):1924-36. doi: 10.1016/j.clinthera.2007.09.018. Clin Ther. 2007. PMID: 18035192 Clinical Trial.
-
Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension.J Cardiovasc Pharmacol. 2010 Dec;56(6):669-75. doi: 10.1097/FJC.0b013e3181fc45bb. J Cardiovasc Pharmacol. 2010. PMID: 20881606 Clinical Trial.
-
Clinical relevance of optimal pharmacokinetics in the treatment of hypertension.J Hypertens Suppl. 1997 Dec;15(5):S27-31. doi: 10.1097/00004872-199715055-00005. J Hypertens Suppl. 1997. PMID: 9481613 Review.
Cited by
-
Isavuconazole and Calcium Channel Blocker for Invasive Fungal Disease Accompanied With Hypertension: Evidence From the FAERS and PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1359-1369. doi: 10.1002/psp4.70056. Epub 2025 Jul 22. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 40694492 Free PMC article.
-
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):443-456. doi: 10.1007/s10928-018-9574-0. Epub 2018 Feb 9. J Pharmacokinet Pharmacodyn. 2018. PMID: 29427135 Free PMC article.
-
Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.Drugs Aging. 1997 Dec;11(6):470-9. doi: 10.2165/00002512-199711060-00006. Drugs Aging. 1997. PMID: 9413704 Review.
-
Therapeutic Approach to Hypertension Urgencies and Emergencies in the Emergency Room.High Blood Press Cardiovasc Prev. 2018 Jun;25(2):177-189. doi: 10.1007/s40292-018-0261-4. Epub 2018 May 18. High Blood Press Cardiovasc Prev. 2018. PMID: 29777395 Review.
-
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.Drugs. 1995 Sep;50(3):560-86. doi: 10.2165/00003495-199550030-00009. Drugs. 1995. PMID: 8521773 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources